Momenta Pharmaceuticals (MNTA) to Release Quarterly Earnings on Monday

Momenta Pharmaceuticals (NASDAQ:MNTA) will be issuing its quarterly earnings data before the market opens on Monday, February 19th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $16.25 on Monday. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $19.55. The company has a market cap of $1,241.29, a P/E ratio of -20.31 and a beta of 1.80.

MNTA has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $15.30.

In related news, Director Elizabeth Stoner sold 5,500 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total value of $72,050.00. Following the sale, the director now owns 13,240 shares of the company’s stock, valued at approximately $173,444. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Insiders sold a total of 63,170 shares of company stock worth $944,353 in the last ninety days. 4.40% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/momenta-pharmaceuticals-mnta-to-release-quarterly-earnings-on-monday.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply